Sanctuary Advisors LLC Acquires 577 Shares of GSK plc (NYSE:GSK)

Sanctuary Advisors LLC raised its holdings in shares of GSK plc (NYSE:GSK) by 0.2% in the third quarter, Holdings Channel.com reports. The firm owned 272,560 shares of the pharmaceutical company’s stock after purchasing an additional 577 shares during the period. Sanctuary Advisors LLC’s holdings in GSK were worth $11,142,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Stock Yards Bank & Trust Co. bought a new position in GSK during the 3rd quarter valued at approximately $210,000. Second Line Capital LLC purchased a new stake in shares of GSK in the third quarter worth $245,000. Rehmann Capital Advisory Group increased its holdings in shares of GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after acquiring an additional 332 shares in the last quarter. TD Private Client Wealth LLC raised its position in shares of GSK by 36.9% in the 3rd quarter. TD Private Client Wealth LLC now owns 12,422 shares of the pharmaceutical company’s stock worth $508,000 after purchasing an additional 3,346 shares during the last quarter. Finally, Sunbelt Securities Inc. boosted its stake in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at GSK

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of GSK stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 19.97 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.00% of the stock is owned by corporate insiders.

GSK Price Performance

Shares of GSK opened at $33.95 on Friday. The firm has a fifty day simple moving average of $36.18 and a two-hundred day simple moving average of $39.28. The firm has a market cap of $70.35 billion, a PE ratio of 22.04, a P/E/G ratio of 1.54 and a beta of 0.64. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a 1-year low of $32.83 and a 1-year high of $45.92.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.63%. The ex-dividend date is Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is 99.35%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GSK. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.